據悉空巴接近獲墨西哥廉航Viva新機合約
格隆匯6月19日丨據市場消息,歐洲飛機制造商空客與墨西哥廉航Viva Aerobus洽商新機訂單的事宜進入後期階段,涉及訂機數量至少超過100架。Viva發言人表示,與空巴仍在洽商訂購A321neo機事宜,但未有簽訂任何協議。發言人補充,洽商的新機預期要到2027年後才會交付。Viva在訂機方面一貫較遊離。該公司在2013年曾經放棄訂購波音新機,轉訂空巴新機,當時的訂機合約面值為40億美元。巴黎航空展將於本週舉行,業界相信,很多航空公司會在期間公佈向波音或空巴訂購新機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.